SVB Leerink analyst Marc Goodman maintained an Outperform rating on Biohaven Pharmaceutical and raised his price target on the shares to $64 from $62 after the company announced that troriluzole successfully passed the interim futility analysis for the 48-week pivotal Phase 2/3 Alzheimer's disease study, noting that the study should now continue on to completion. Goodman said that this is good news for Biohaven as AD is a high unmet need disease with few products approve, and also it begins to validate the glutamate platform in light of many investors being "solely focused" on th lead migraine asset rimegepant. The analyst added that he is now increasing probability of success for troriluzole in AD to 35% from 20% on this "positive" result.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here